Rolnick S J, Kopher R, Jackson J, Fischer L R, Compo R
HealthPartners Research Foundation, Minneapolis, Minnesota 55440-1524, USA.
Menopause. 2001 Summer;8(2):141-8. doi: 10.1097/00042192-200103000-00010.
To assess whether osteoporosis education, with and without bone mineral density (BMD) testing, increases the initiation of lifestyle changes and pharmaceutical treatment to prevent osteoporosis.
A total of 508 women, aged 54-65, from a large managed care organization who were not on osteoporosis prevention therapy participated in an intervention study. Participants were randomly assigned to either an education class on osteoporosis (n = 301) or education plus BMD (n = 207). A control group of 187 women receiving no intervention were also surveyed to serve as comparison. Group differences and differences based on BMD test result were compared 6 months after education regarding self-reported changes in health behaviors using chi2 tests and logistic regression analyses.
Of the 508 intervention participants, 455 (90%) responded to the follow-up survey. Initiation of hormone replacement therapy was reported by 9%, with 5% reporting starting alendronate. More than half reported changes in diet, exercise, or calcium intake. Forty-three percent increased their vitamin D intake. There were no significant group differences in behavior except with regard to pharmaceutical therapy; subjects with education plus BMD were three times more likely than those receiving education only to report starting hormone replacement therapy (p = 0.004). Low BMD scores were associated with increasing vitamin D intake (p = 0.03) and starting medication (p = 0.001). Women in the intervention groups were significantly more likely to report modifying their diet (p < 0.001), calcium (p < 0.01), and vitamin D intake (p < 0.0001) than women in the control group, not exposed to education.
Education regarding osteoporosis prevention seems to encourage women to make lifestyle changes. The inclusion of BMD testing enhances the likelihood that women will consider pharmaceutical therapy.
评估骨质疏松症教育(无论是否进行骨密度测试)能否增加为预防骨质疏松症而进行生活方式改变及药物治疗的起始率。
来自一家大型管理式医疗组织、年龄在54 - 65岁且未接受骨质疏松症预防治疗的508名女性参与了一项干预研究。参与者被随机分为骨质疏松症教育组(n = 301)或教育加骨密度测试组(n = 207)。另外选取187名未接受干预的女性作为对照组进行调查以作比较。在教育6个月后,使用卡方检验和逻辑回归分析比较了各组之间以及基于骨密度测试结果的自我报告健康行为变化的差异。
508名干预参与者中,455名(90%)对随访调查作出了回应。报告开始激素替代疗法的占9%,5%报告开始使用阿仑膦酸盐。超过一半的人报告了饮食、运动或钙摄入量的变化。43%的人增加了维生素D的摄入量。除药物治疗外,行为方面无显著组间差异;接受教育加骨密度测试的受试者报告开始激素替代疗法的可能性是仅接受教育者的三倍(p = 0.004)。低骨密度评分与增加维生素D摄入量(p = 0.03)和开始用药(p = 0.001)相关。与未接受教育的对照组女性相比,干预组女性更有可能报告改变饮食(p < 0.001)、钙摄入量(p < 0.01)和维生素D摄入量(p < 0.0001)。
关于骨质疏松症预防的教育似乎鼓励女性改变生活方式。纳入骨密度测试增加了女性考虑药物治疗的可能性。